LY 03005

Drug Profile

LY 03005

Alternative Names: 4-Methylbenzoate desvenlafaxine hydrochloride; Desvenlafaxine prodrug; LY03005

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Luye Pharma Group
  • Class Antidepressants; Benzoates; Cyclohexanols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Major depressive disorder

Most Recent Events

  • 22 Dec 2017 Luye Pharma Group completes a phase I trial in Major depressive disorder (In volunteers) in USA (PO) (NCT03357796)
  • 04 Dec 2017 LY 03005 is still in phase I trials for Major depressive disorders in USA (NCT03357796)
  • 27 Nov 2017 Phase-I clinical trials in Major depressive disorder (In volunteers) in USA (PO) (NCT03357796)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top